views
Treatment of atrophic vaginitis includes use of lubricants, moisturizers and low-dose vaginal estrogen therapy. Vaginal estrogen therapy is the most effective treatment method which is usually prescribed in the form of creams, tablets or rings. The global atrophic vaginitis treatment market is estimated to be valued at US$ 758.4 Bn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the atrophic vaginitis treatment market are United Company RUSAL Plc, Alcoa Inc., Aluminum Corp. of China Ltd., Kaiser Aluminum Corporation, Norsk Hydro ASA, Dubai Aluminum Co., Constellium, Kobe Steel, Ltd., and Aluminum Bahrain B.S.C. These players are focused on developing new products and adopting inorganic growth strategies like collaborations and partnerships to expand their market share.
The increasing global geriatric population suffering from menopause and hormonal imbalance is expected to create numerous growth opportunities in the market. Companies are investing heavily in R&D to develop new drug formulations and treatment methods to capitalize on this opportunity.
The global leaders are expanding their operations in emerging markets of Asia Pacific and Latin America through strategies like joint ventures and acquisitions. The low manufacturing costs and growing healthcare investments in these regions are attracting large investments.
Market Drivers
Rising Prevalence of Menopause: The increasing prevalence of menopause worldwide due to rapidly growing elderly population base is a major factor boosting market growth. It is estimated that over 1 billion women worldwide will be in menopause by 2025.
Growing Awareness: Rising awareness about treatment options and available therapies for atrophic vaginitis is encouraging more women to seek medical help, driving market revenues.
Market Restraints
Side Effects of Estrogen Therapies: Though estrogen-based therapies are very effective, they may cause side effects like breast pain, menstrual irregularities, nausea etc. in some women which limits their uptake.
Lack of Treatment Options: There exist only a few approved therapies for atrophic vaginitis and unmet needs persist regarding alternate new treatment modalities which challenges market potential.
Segment Analysis
The Atrophic Vaginitis Treatment Market Scope is segmented based on type, treatment, distribution channel, and region. In terms of type, the market is divided into mild, moderate, and severe atrophic vaginitis. The moderate segment holds the largest market share owing to increasing prevalence of menopause that leads to moderate symptoms of atrophic vaginitis in women. Treatment-wise, the market is classified into estrogen therapy, estrogen-antimuscarinic therapy, and other therapies. Within these, estrogen therapy accounts for the dominant share as it is considered as the standard treatment recommended for women suffering from atrophic vaginitis.
Global Analysis
Regionally, North America commands the major share in the atrophic vaginitis treatment market due to growing female geriatric population experiencing menopause and related vaginal health issues. Also, higher per capita income enables better access to quality treatment in the region. On the other hand, Asia Pacific is pegged to witness the highest growth during the forecast period. This is attributed to improving healthcare infrastructure, increase in healthcare expenditures, rising awareness about women's health issues, and gradual adoption of latest treatment options. Japan, China, and India emerge as highly lucrative Asian markets.
Get More Insights On Atrophic Vaginitis Treatment Market
Comments
0 comment